📰 Study May Proceed News
Page 2 - Study May Proceed News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Study May Proceed. Real-time updates on events, politics, business and more.
February 15, 2022
/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development...
February 15, 2022
/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development...
February 7, 2022
SYDNEY, Feb. 7, 2022 /PRNewswire/ — Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the...
February 4, 2022
04.02.2022 - - Tiziana is Developing the First Oral Form of Foralumab in a Convenient Capsule to be Evaluated in Phase 1b Clinical Study NEW YORK, Feb. 04, 2022 (GLOBE NEWSWIRE) - Tiziana Life Sciences Ltd (Nasdaq: TLSA) (“Tiziana” or the “Company”), a ... Seite 1
February 4, 2022
- Tiziana is Developing the First Oral Form of Foralumab in a Convenient Capsule to be Evaluated in Phase 1b Clinical Study NEW YORK, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (Nasdaq:
February 4, 2022
- Tiziana is Developing the First Oral Form of Foralumab in a Convenient Capsule to be Evaluated in Phase 1b Clinical Study NEW YORK, Feb. 04, 2022 -- Tiziana Life Sciences Ltd , a biotechnology... | February 4, 2022
January 5, 2022
/PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course...
January 5, 2022
/PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course...
October 27, 2021
Investegate announcements from Curium, Curium Initiates ECLIPSE, a Phase 3 Clinical Trial For Its Investigational Lu 177 PSMA I&T
April 16, 2021
Share this article Share this article STUART, Fla., April 16, 2021 /PRNewswire/ -- Stuart Therapeutics (Stuart) announced today that the U.S. Food and Drug Administration (FDA) has completed its review of an Investigational New Drug (IND) application for Stuarts investigational product ST-100, a topical drop formulation designed to treat ocular surface diseases, including dry eye disease, an indication that affects nearly 10% of the United States population. As a result of this review, the FD...